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Objectives. The purpose of this study was to investigate the 
peroxidative susceptibility of plasma low density lipoprotein in 
patients with active variant angina and to compare it with that in 
subjects without coronary spasm. 
Background. Oxidized or modified low density lipoprotein can 
impair endothelium-dependent vasoregulation and has athero- 
genic properties; it may be related to the genesis of coronary 
artery spasm by potentiating agonist-induced vasoconstriction. 
Methods. The sensitivity of plasma low density lipoprotein for 
cupric ion (CuZ+)-induced peroxidation was examined. Low den- 
sity lipoprotein was isolated from plasma in 112 patients: 21 with 
active variant angina, 18 with inactive variant angina without 
anginal attacks during the preceding 6 months, 39 with significant 
organic coronary artery stenoses but without rest angina and 34 
control subjects without coronary artery disease. Lipid peroxida- 
tion products in low density fipoprotein were assayed as thiobar- 
bituric acid-reactive substances before and after incubation with 
various concentrations of Cu 2+ at 37°C for 24 h. 
Results. Significantly higher levels of generation of thiobarbi- 
turic acid-reactive substances from plasma low density lipopro- 
tein after incubation with Cu 2+ were seen in patients with active 
variant angina than in patients in the other three groups. The 
dose-response curve of low density lipoprotein peroxidation in- 
duced by Cu 2+ shifted to the left in this group as compared with 
the curve in the other three groups. The vitamin E (alpha- 
tocopheroi) content of low density lipoprotein fraction in these 
patients was significantly lower than that in the other groups. 
After >6 months of an angina-free period in five patients with 
active variant angina, thiobarbituric acid-reactive substances 
induced by 0.5 pmol/liter Cu 2+ in low density lipoprotein were 
significantly decreased and vitamin E content was significantly 
increased. 
Conclusions. These results indicate that vitamin E-deficient 
plasma low density lipoprotein in patients with active variant 
angina is highly susceptible to peroxidative modification. 
(J Am Coll Cardiol 1995;26:632-8) 
Coronary artery spasm has been appreciated as one cause of 
anginal attacks in a wide spectrum of ischemic heart diseases 
(1,2). Recently, oxidized low density lipoprotein has received 
increasing attention because of its potential cytotoxic and 
atherogenic properties (3). In addition, it has been shown to 
cause impairment of endothelium-dependent vasoregulation 
(4) and to potentiate agonist-induced vasoconstriction by a 
direct action on vascular smooth muscle (5). However, it is not 
known whether oxidized low density lipoprotein is related to 
the genesis of coronary artery spasm. 
The conversion from native low density lipoprotein to the 
oxidized form, which takes place in the subendothelium, ay 
be regulated by the propensity for low density lipoprotein to 
undergo lipid peroxidation. Thus, we hypothesized that the 
susceptibility of plasma low density lipoprotein to oxidative 
modification would differ in patients with variant angina and 
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normal subjects. In the present study the thiobarbituric acid 
reaction, a simple and sensitive known method, was used to 
monitor products of low density lipoprotein lipid peroxidation 
before and after incubation with various concentrations of
cupric ion (Cu e+ ) in patients with active or inactive variant 
angina, organic coronary artery stenoses and control subjects. 
Because low density lipoprotein is known (6) to carry the 
antioxidant alpha-tocopherol (vitamin E), we also hypothe- 
sized that vitamin E as a major antioxidant would be reduced 
in patients with active variant angina. Vitamin E content was 
determined in low density lipoprotein from these subjects. 
Methods  
Patients (Table 1). Twenty-one patients (Group 1, 17 men 
and 4 women with a mean age of 57 years) with active variant 
angina who had at least one anginal attack/day during a 3-day 
observation period were studied. Fourteen (67%) were current 
smokers, two were former smokers and five were nonsmokers. 
In all 21 patients, multivessel coronary artery spasm with 
ischemic electrocardiographic ST segment deviation was veri- 
fied by intracoronary injection of ace@choline. Thirteen pa- 
tients (62%) had positive treadmill exercise test results with 
anginal attacks in association with ST segment elevation. 
~'11995 by the Amcricall ('~llcgc ol (':tldiolog~ 0735-1097/95/$9.50 
0735-1097(95)00207-K 
,IACC Vol. 26, No. 3 MIWA ET AL. 633 
September 1995:632-8 LOW DENSITY LIPOPROTEIN IN VARIANT ANG1NA 
Table 1. Clinical Characteristics of Patients in the Four Study Groups 
Group 1 Group 2 Group 3 Group 4* 
(n = 21) (n - 18) (n = 39) (n = 34) 
Male/female 17/4 16/2 31/8 23/11 
Mean age (yr) 57 56 59 54 
Current smoker 14 (67%)3 2 (11%) 15 (38%) 12 (35%) 
Organic coronary stenoses (->75%) 10 (48%) 9 (50%) 39 (100%) 0/22 (0%) 
*Twenty-two f the 34 patients in this group underwent coronary arteriography, tP < 0.05 versus the other three 
groups. Unless otherwise indicated, data are expressed as number (%) of patients. Group 1 = patients with active variant 
angina; Group 2 = patients with inactive variant angina; Group 3 = patients with organic coronary artery stenoses 
without rest angina; Group 4 = control subjects without coronary artery disease. 
Anginal attacks with ST segment elevation were also provoked 
during the hyperventilation test in 16 (76%). 
Three other patient groups were studied. Group 2 com- 
prised 18 patients with inactive variant angina who had no 
anginal attacks during the preceding 6 months while receiving 
medical treatment with calcium channel blocking agents and 
during a 3-day observation period without medication. This 
group consisted of 16 men and 2 women (2 current smokers, 13 
former smokers and 3 nonsmokers) with a mean age of 56 
years. Group 3 comprised 39 patients with significant coronary 
artery organic stenoses but without rest angina. They were 31 
men and 8 women (15 current smokers, 17 former smokers and 
7 nonsmokers) with a mean age of 59 years. Group 4 com- 
prised 34 subjects without coronary artery disease. They were 
23 men and ll women (12 current smokers, 10 former smokers 
and 12 nonsmokers) with a mean age of 54 years. Sixteen 
patients in this group had atypical chest pain, 11 had valvular 
heart disease, 4 had arrhythmias, 2had cardiomyopathy and 1 
had mild hypertension; all 34 had negative treadmill exercise 
test results. No significant organic oronary artery stenosis was 
demonstrated in any of the 22 patients in this group who 
underwent coronary arteriography. 
Current smokers were significantly (p < 0.05) more preva- 
lent in Group 1 (67%) than in the other three groups (11% in 
Group 2, 38% in Group 3, 35% in Group 4). Patients with 
familial hypercholesterolemia andpatients receiving any drugs 
containing vitamin E or vitamin C were excluded from the 
study. All current smokers had smoked >-10 cigarettes/day for 
>1 year and all former smokers had stopped smoking ->6 
months before the study. All studies were approved by the 
local ethics committee and all patients gave written informed 
consent. 
Procedures. All drugs except nitroglycerin were discontin- 
ued for ---24 h before the study, and all blood samples were 
taken from patients in the fasting state in the morning. Blood 
( -  14 ml) was drawn into vacutainer tubes containing ethylenedi- 
aminetetraacetic acid disodium salt. Plasma was immediately 
separated by centrifugation and stored at 4°C until use. 
Plasma low density lipoprotein was prepared by sequential 
ultracentrifugation at preselected densities (1.019 to 1.063) as 
previously described (7). The protein concentration of low 
density lipoprotein was then determined according to the 
method of Lowry et al. (8) with bovine serum albumin as 
standard. Low density lipoprotein was then dialyzed against 
M/15 phosphate buffer solution, pH 7.4, at 4°C for 40 to 48 h. 
It was sterile filtered, separated by aliquots into plastic tubes 
and kept in darkness at 4°C. The resultant low density lipopro- 
tein samples (45/xg) were incubated in a total volume of 300/xl 
phosphate-buffered saline solution (M/15 sodium phosphate 
buffer, pH 7.4, containing 150 mmol/liter sodium chloride) at 
37°C for 24 h in a carbon dioxide incubator in the absence or 
presence of various concentrations (0.01 to 5 /xmol/liter) of 
copper sulfate. Lipid peroxide formation was estimated as 
thiobarbituric acid-reactive substances by using a lipoperoxide 
test kit (Wako, Osaka, Japan) according to the method of 
Heinecke t al. (9) with a slight modification (10). Low density 
lipoprotein (10 txg of protein) was suspended in 1.5 ml of 150 
retool/liter sodium chloride, and the suspension was mixed with 
0.5 ml of 20% trichloroacetic acid and 0.5 ml of thiobarbituric 
acid reagent (0.67% thiobarbituric acid aqueous solution/ 
glacial acetic acid, 1:1, vol/vol) and boiled at 95°C for 60 min. 
The mixture was cooled with water and shaken vigorously with 
2.0 ml of n-butanol for at least 15 s. After centrifugation at 
3,000 rpm for 20 min, the n-butanol layer was removed, and the 
fluorescence was measured on a fluorescence spectrophotom- 
eter with excitation at 515 nm and emission at 550 nm. 
Tetramethoxypropane wasused as a standard and results were 
expressed as nmol of malondialdehyde equivalents. 
Vitamin E content in low density lipoprotein fraction was 
estimated by the high performance liquid chromatography 
method of Thompson and Hatina (11) with vitamin E acetate 
as internal standard added before lipid extraction. Vitamin E 
content was expressed as/~g/mg protein. 
The entire process of the experimental procedures was 
completed within 3 weeks. 
Statistical analysis. The data shown represent mean value 
_+ SEM; statistical significance was determined by Student 
paired and unpaired t tests. Intergroup comparisons concern- 
ing the dose-response r lation of generation of thiobarbituric 
acid-reactive substances in low density lipoprotein induced by 
Cu 2+ were made with a Bonferroni multiple comparisons test 
after being analyzed by analysis of variance (ANOVA) for 
repeated measures. Significance was defined at the p < 0.05 
level. 
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Table 2. Plasma Levels of Triglycerides and Total and High and 
Low Density Lipoprotein Cholesterol* 
Cholesterol (mg/dl) 
Trigtyeerides 
Group (mg/dl) Total HDL LDL 
1 138 ± 6? 185 + 6 41 ± 4 116 = 6 
2 120 ± 6 200 ± 7 45 _+ 2 131 : 8 
3 126 + 8 198_+ 11 39 ± 3 134 ~ 9 
4 127_+7 187+_10 47±6 115±8 
*Plasma low density lipoprotein (LDL) cholesterol level was calculated by 
using the formula: LDL cholesterol : Total cholesterol minus high density 
lipoprotein (HDL) cholesterol minus (triglyceride divided by 5). tp < 0.05 versus 
Group 2. Data are expressed as mean value ± SEM. Groups as defined in 
Table 1. 
Results 
The results are summarized in Tables 2 and 3. The plasma 
triglyeeride l vel in Group 1 was significantly (p < 0.05) higher 
than that in Group 2. Although the plasma level of high density 
lipoprotein cholesterol tended to be lower in Groups 1 and 3, 
and total cholesterol and low density lipoprotein cholesterol 
higher in Groups 2 and 3, there were no significant differences 
in the plasma levels of total cholesterol, ow density lipoprotein 
cholesterol and high density lipoprotein cholesterol among the 
four groups (Table 2). 
Thiobarbituric acid-reactive substances formed by low 
density lipoprotein isolated from plasma. The mean stock 
time of the isolated and dialyzed low density lipoprotein 
fraction before the CuZ+-induced peroxidation did not differ 
among groups (3 +_ 1 days in Groups 1, 2 and 3; 4 +_ 1 days in 
Group 4). The thiobarbituric acid-reactive substances level 
detected in flesh low density lipoprotein was trace level and 
comparable among the four groups (Table 3). After incubation 
without Cu 2+ at 37°C for 24 h, the detected production level of 
thiobarbituric acid-reactive substances was also low and the 
amount of thiobarbituric acid-reactive substances did not 
differ among the four groups, although it was slightly higher in 
Group 1. However, after incubation with Cu 2+, the level of 
thiobarbituric acid-reactive substances in low density lipopro- 
tein in Group 1 differed significantly from levels in the other 
three groups (p < 0.05 by ANOVA). Significantly (p < 0.01) 
greater production of thiobarbituric acid-reactive substances 
in low density lipoprotein after incubation with 0,5, 1, 2 or 
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Figure 1. Dose-response curves of plasma low density lipoprotein 
oxidation induced by cupric ion (Cu2+). Low density lipoprotein 
samples were prepared from the plasma of four groups of patients. 
Incubation of low density lipoprotein with various concentrations of
copper sulfate (CuSQ) was carried out at 37°C for 24 h. The assay of 
thiobarbituric acid-reactive substances (TBARS) was carried out as 
described in Methods. The dose-response curve of Group I (patients 
with active variant angina) was significantly different from that in 
Group 2 (patients with inactive variant angina), Group 3 (patients with 
organic coronary artery stenoses without rest angina) and Group 4 
(control subjects without coronary artery disease). Data are expressed 
as mean value _ SEM (bars). *p < 0.05 versus Group 2 and p < 0.0l 
versus Groups 3 and 4. tp < 0.01 versus Groups 3 and 4. MDA = 
malondialdehyde. 
5/xmol/liter Cu 2+ was found in Group 1 than in Groups 3 and 
4. Also, a significantly (p < 0.05) greater amount of thiobar- 
bituric acid-reactive substances production in low density 
lipoprotein after incubation with 0.5 or 1/xmol/liter Cu 2÷ was 
found in Group 1 than in Group 2, although this difference was 
not significant after incubation with 2 or 5 txmol/liter Cu 2+. 
The dose-response curve of Cu 2"-induced production of thio- 
barbituric acid-reactive substances in Group 1 appeared to be 
shifted to the left as compared with those in the other three 
groups (Fig. 1). 
Proteolytic degeneration of apolipoprotein B of low density 
lipoprotein was demonstrated by sodium dodecylsulfate poly- 
acrylamide gradient gel electrophoresis a the apolipoprotein 
B band disappeared from low density lipoprotein after incu- 
bation with 5/xmol/liter Cu 2- (data not shown). Agarose gel 
electrophoresis demonstrated that low density lipoprotein in- 
creased its negative charges after incubation with Cu 2+ com- 
pared with its native form (data not shown). 
Table 3. Oxidation of Low Density Lipoprotein Induced by Cupric Ion (Cu z÷) 
Thiobarbituric A id-Reactive Substances (nmol of MDA/mg protein) 
Before After Incubation With Cu 2- at 37°C for 24 h (/zmol/liter Cu 2-) 
Group Cu 2+ 0 0.1 0.2 0.5 1 2 5 
1 1.4 + 0.5 2.5 _+ 0.5 3.8 _+ 0.7 5.8 +_ 1.3 17.3 _+ 3.3* 25.8 +- 5.7* 29.9 ± 5.2? 34.3 + 5.0? 
2 1.1 + 0.2 1.6 _+ 0.2 2.5 ± 0.4 4.0 ± 0.9 9.4 _+ 2.0 16.8 -+ 2.8 24.9 +- 3.6 31.4 _+ 2.8 
3 1.2 _* 0.4 1.9 ± 0.2 2.4 _+ 0.4 4.1 + 0.9 8.0 ± 1.6 12.0 ± 2.3 16.8 ± 2.6 26.0 -- 2.3 
4 0.8 _ 0.2 1.7 z 0.2 2.5 ± 0.8 3.6 ± 0.9 6.0 ± 1.2 12.6 ± 2.4 17.7 -+ 2.2 24.6 _+ 1.9 
*p < 0,05 versus Group 2, p < 0.0l versus Groups 3 and 4, tp < 0.01 versus Groups 3 and 4. Data are expressed as mean value ± SEM. MDA = malondialdehyde. 
Groups as defined in Table 1. 
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Figure 2. Vitamin E (alpha-tocopherol) content in low density li- 
poprotein. Data are expressed as mean value (columns) -+ SEM 
(bars). Numbers in parentheses indicate number of patients. Groups 
as defined in Figure I. 
Vitamin E content of low density lipoprotein. Vitamin E 
content in low density lipoprotein fraction of each group is 
shown in Figure 2. The vitamin E level in Group 1 (0.85 _ 
0.14/~g/mg protein) was significantly lower than that in Group 
2 (1.83 ___ 0.24 /zg/mg protein, p < 0.01), Group 3 (1.32 +_ 
0.13/xg/mg protein, p < 0.05) and Group 4 (1.67 +_ 0.15/zg/mg 
protein, p < 0.01). The level in Group 3 tended to be lower 
than that in Groups 2 and 4 (p = NS). 
Effects of smoking on oxidative susceptibility and vitamin E 
content of low density lipoprotein (Fig. 3 and 4). The amount 
of thiobarhituric acid-reactive substances induced by 0.5/~mol/ 
liter Cu 2+ in low density lipoprotein was not significantly 
different between smoking and nonsmoking subjects in each 
subgroup. Among current smokers, however, the amount was 
Figure 3. Production of thiobarbituric acid-reactive substances in- 
duced by 0.5 ~mol/liter cupric ion (Cu 2+) in low density lipoprotein 
compared in smokers (hatched columns) and nonsmokers (open 
columns). Patients were classified as smokers or nonsmokers according 
to their current smoking status. Values (in nmol of malondialde- 
hyde/rag protein) were as follows in smokers: 17.5 • 4.7 (Group 1), 
8.7 +- 2.6 (Group 3), 8.4 + 2.3 (Group 4) and 9.0 + 1.7 (Group 2 + 3 
+ 4). In nonsmokers, values were 16.9 + 5.8 (Group 1), 7.5 _+ 1.9 
(Group 3), 4.7 + 1.4 (Group 4) and 6.8 - 1.0 (Group 2 + 3 + 4). Data 
are expressed as mean value (columns) + SEM (bars). Numbers in 
parentheses indicate number of patients. Groups and abbreviations a
in Figure 1. 
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Figure 4. Vitamin E (alpha-tocopherol) content in low density li- 
poprotein compared in smokers and nonsmokers. Patients were clas- 
sified as smokers (hatched columns) or nonsmokers (open columns) 
according to their current smoking status. Values (in/~g/mg protein) 
were as follows in smokers: 0.85 -+ 0.14 (Group 1), 1.08 _+ 0.20 (Group 
3), 1.09 + 0.15 (Group 4) and 1.18 _+ 0.12 (Group 2 + 3 + 4). In 
nonsmokers, values were 0.85 z 0.23 (Group 1), 1.46 + 0.18 (Group 
3), 1.49 +- 0.17 (Group 4) and 1.54 + 0.11 (Group 2 + 3 + 4). Data are 
expressed as mean value (columns) -2-- SEM (bars). Numbers in paren- 
theses indicate number of patients. Groups as defined in Figure 1. 
significantly (p < 0.05) greater in Group 1 than in the other 
three groups combined. Among current nonsmokers, the 
amount was also significantly (p < 0.01) greater in Group 1 
than in Group 3, Group 4 and the combined groups except 
Group 1 (Fig. 3). The vitamin E content of low density 
lipoprotein was comparable in smokers and nonsmokers in 
Group 1, but it was significantly (p < 0.05) lower in the 
smokers in the combined groups except Group 1. The vitamin 
E content in low density lipoprotein was significantly (p < 
0.05) lower in Group 1 than in the combined groups except 
Group 1 in smoking as well as nonsmoking patients (Fig. 4). 
Follow-up data on variant angina. Group 1 patients were 
followed up with medication including a sutficient dose of 
calcium channel blockers to prevent he occurrence of anginal 
attacks. Blood samples were obtained in five of these patients 
who had had no angina for ->6 months. Low density lipopro- 
rein fraction was isolated and both Cu2+-induced thiobarbitu- 
tic acid-reactive substances production and vitamin E content 
were assayed. As shown in Figure 5, the 0.5 tzmol/liter Cu 2+- 
induced production of thiobarbituric acid-reactive substances 
in low density lipoprotein significantly decreased (from 23.8 + 
3.8 to 12.4 - 3.3 nmol of malondialdehyde/mg protein, p < 
0.05) and the vitamin E content in low density lipoprotein 
fraction significantly increased (from 0.48 + 0.14 to 1.43 + 
0.26/zg/mg protein, p < 0.05) after the complete disappear- 
ance of angina in these patients. All five patients were current 
smokers. They quit smoking during the follow-up period. 
Discuss ion  
Our results clearly demonstrated that plasma low density 
lipoprotein in patients with variant angina is highly susceptible 
to peroxidative modification as compared with that in patients 
without a coronary spastic tendency. Moreover, this high 
susceptibility of low density lipoprotein to lipid peroxidation i
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Figure 5. Follow-up data of 0.5/~mol/ 
liter cupric ion-induced production 
of thiobarbituric a id-reactive sub- 
stances (TBARS) (left panel) and vi- 
tamin E (a-tocopherol) content 
(fight panel) in low density lipopro- 
rein (LDL) in five patients (Group 1) 
with active variant angina. The fol- 
low-up data are based on blood sam- 
ples obtained from these patients who 
had had no angina for >-6 months. 
Data are expressed asindMdual val- 
ues (closed circles) and mean value 
(wide bars) + SEM (narrow bars). 
MDA = malondialdehyde. 
active variant angina was found to have been corrected after 
the inactivation of the tendency to coronary spasm. This 
observation suggests that 1) oxidized low density lipoprotein 
formation may play an important role in the pathogenesis of
coronary artery spasm, and 2) the susceptibility of low density 
lipoprotein to oxidative modification may be a generalized 
contributing factor to multivessel spasm observed in most 
patients with variant angina (12-14). 
Earlier studies (15-17) have demonstrated a hyperrespon- 
siveness of arteries from hypercholesterolemic animals to 
various vasoconstrictors. This hyperresponsiveness could be 
explained at least in part by a suppressed production of 
endothelium-dependent relaxing factors from the damaged 
endothelium. In the rabbit aorta, low density lipoproteins 
inhibit endothelium-dependent relaxations to acetylcholine 
and in the porcine coronary artery to serotonin (4,18). There- 
fore, low density lipoprotein and, in particular, its oxidized 
form may specifically interact with endothelial cells and pro- 
mote functional alterations. Increased content of lysophos- 
phatidylcholine in modified low density lipoprotein has been 
demonstrated to play an important role in impairment of 
endothelium-dependent arterial relaxation (4). 
It is controversial whether oxidized low density lipoprotein 
is present in circulating plasma, but recent investigations (3,19) 
support he concept hat oxidative modification of low density 
lipoprotein takes place in vivo. Antibodies against epitopes of 
oxidized low density lipoprotein recognize materials in athero- 
sclerotic lesions of rabbits and humans, but not in normal 
arteries (20,21). Low density lipoprotein extracted from human 
atherosclerotic lesions contains nearly all of the physicochem- 
ical and immunologic properties of in vitro oxidized low 
density lipoprotein (22). Indeed, antioxidant drugs such as 
probucol can inhibit atherosclcrosis in hypercholesterolemic 
rabbits (23). 
Freshly isolated low density lipoprotein from plasma was 
almost free of detectable amounts of lipid peroxides in basal 
conditions in all four of our patient groups suggesting that the 
conversion from native low density lipoprotein to the oxidized 
form will take place not in human plasma but in the subendo- 
thelial space after penetration of low density lipoprotein to the 
subendothelial space or during the process of the penetration. 
Formation of oxidized low density lipoprotein can induce 
endothelial damage and thus facilitate the atherogenic process 
by allowing entry of elements from the blood and by allowing 
adherence of platelets. Additional properties of oxidized low 
density lipoprotein that may make it more atherogenic nclude 
its interference with the response of arteries to endothelium- 
dependent relaxing factors (21,22). The precise mechanism by 
which oxidized low density lipoprotein impairs endothelial 
cell-mediated smooth muscle relaxation remains uncertain. 
Both the inhibition of production of endothelium-dependent 
relaxing factors (24) and their inactivation resulting in the 
inhibition of the production of cyclic guanine monophosphate 
have been suggested (25) as possible mechanisms. In addition, 
oxidized low density lipoprotein has been shown to potentiate 
agonist-induced vasoconstriction bya direct effect on vascular 
smooth muscle (5). 
Susceptibility of plasma low density lipoprotein to oxida- 
tion and vitamin E content. The underlying mechanisms of 
the high susceptibility of plasma low density lipoprotein to 
oxidation remain to be elucidated. In the present study the 
vitamin E level in low density lipoprotein from patients with 
active variant angina was significantly lower than that from 
control subjects, and this vitamin E deficiency in low density 
lipoprotein had been corrected in inactive patients with variant 
angina. Vitamin E represents a protective system for low 
density lipoprotein particles, as only vitamin E-depleted low 
density lipoprotein is oxidized (26). The deficiency in antioxi- 
dants such as vitamin E in plasma low density lipoprotein may 
be an important factor in the susceptibility of low density 
lipoprotein to oxidation (26,27). Cigarette smoke also may 
influence the metabolic fate of low density lipoprotein. An 
extract of cigarette smoke was demonstrated to modify low 
density lipoprotein and to cause increased shunting of such 
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modified low density lipoprotein into macrophages, converting 
them to foam cells (10), It can be speculated that vitamin E is 
consumed to scavenge low density lipoprotein-modifying rad- 
icals in heavy smokers. When vitamin E was assessed as a 
major antioxidant in low density lipoprotein from smokers and 
nonsmokers, its concentration was found to be lower in the low 
density lipoprotein of smokers than of nonsmokers. Schetfler et 
al. (27) reported a similar difference between the low density 
lipoprotein of smokers and nonsmokers. Partial oss of vitamin 
E might reduce the resistance of low density lipoprotein 
against reactive oxygen species. In our patients the vitamin E 
content of low density lipoprotein was potentially influenced by 
smoking because, in contrast o the patients with inactive 
variant angina, most patients with active variant angina were 
current smokers. A higher level of vitamin E content in low 
density lipoprotein in patients with inactive variant angina may 
be due to changes in life-style including changes in smoking 
status, diet, weight, activity level and stress circumstance. Both 
production of thiobarbituric acid-reactive substances in low 
density lipoprotein induced by Cu 2+ and vitamin E content in 
low density lipoprotein in smokers with active variant angina 
were significantly different from levels in patients without 
active variant angina. This difference was more striking in 
nonsmokers with and without active variant angina. Obviously 
other unknown factors in addition to smoking may be involved 
in the low vitamin E content and the high susceptibility to lipid 
peroxidation of low density lipoprotein in patients with active 
variant angina. Moreover, low density lipoprotein or plasma 
alpha-tocopherol levels do not always correlate with the resis- 
tance to oxidation, as reported previously (28,29). Further 
examination isrequired to determine the relation between the 
oxidizability of low density lipoprotein and its vitamin E 
content. 
Methodologic onsiderations and potential imitations. Our 
study has a methodologic limitation. Although we used a wide 
range of concentration of Cu z+ to oxidize low density lipopro- 
tein, oxidation with a higher concentration of >0.5 p~mol/liter 
Cu 2+ for 24 h may be too long, and the lag time between the 
initiation of an oxidative stress and the appearance of the 
propagation phase of lipid peroxidation may be a more ade- 
quate description of the susceptibility of a low density lipo- 
protein particle to oxidation. In a recent report, oxidative 
susceptibility was shown to be increased in small, dense and 
triglyceride-rich low density lipoproteins (30). Low density 
lipoprotein particle sizes were not determined in the present 
study. Because the plasma level of triglyeeride was significantly 
greater in patients with active than with inactive variant angina, 
it may be that the increased amount of small, dense, low 
density lipoproteins i related to the increased susceptibility in 
patients with active variant angina (30). The vitamin E content 
of denser subfractions of low density lipoprotein has been 
reported (31) to be decreased when expressed relative to 
protein. 
Clinical implications. Future studies are needed to eluci- 
date whether antioxidant therapy with vitamin E supplemen- 
tation (32) or cholesterol-lowering drugs such as probucol that 
protect low density lipoprotein from oxidative modification 
(23) is effective treatment for coronary artery spasm in patients 
with variant angina. It should also be determined whether 
myocardial ischemic attacks may be directly related to a low 
content of vitamin E in low density lipoprotein and high 
susceptibility to low density lipoprotein oxidation in patients 
with variant angina. 
In conclusion, circulating plasma low density lipoprotein in 
patients with active variant angina was highly susceptible to 
peroxidative modification in association with less vitamin E 
content han that in patients with inactive coronary spasm. 
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